1. Reliability, Validity, and Responsiveness of the Daily Sleep Interference Scale Among Diabetic Peripheral Neuropathy and Postherpetic Neuralgia Patients 
Margaret K. Vernon, PhD, Nancy A. Brandenburg, PhD, Jose Ma. J. Alvir, DrPH, Teresa Griesing, PhD, Dennis A. Revicki, PhD 
Journal of Pain and Symptom Management 
Volume 36, Issue 1, Pages (July 2008)
DOI: /j.jpainsymman
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1 Weekly mean DSIS for DPN and PHN patient groups over time.
Journal of Pain and Symptom Management  , 54-68DOI: ( /j.jpainsymman )
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2
Mean weekly Sleep Interference Score by MOS-SS Sleep Disturbance Score groups in diabetes and postherpetic patients at baseline. DPN: F=78.45; P<0.001; PHN: F=109.59; P<0.001.
Journal of Pain and Symptom Management  , 54-68DOI: ( /j.jpainsymman )
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
Mean weekly Sleep Interference Score by MPQ-SF VAS Score in diabetes and postherpetic patients at Week 1. DPN: F=190.15; P<0.001; PHN: F=92.07; P< Scheffe post hoc tests showed that all groups were significantly different at the P<0.001 level.
Journal of Pain and Symptom Management  , 54-68DOI: ( /j.jpainsymman )
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions

5. Fig. 4
Mean change in weekly Sleep Interference Score by PGIC Scores from baseline to end of treatment (Week 12) in diabetes patients. F=29.11; P<0.001.
Journal of Pain and Symptom Management  , 54-68DOI: ( /j.jpainsymman )
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions

6. Fig. 5
Mean change in weekly Sleep Interference Scores by PGIC Scores from baseline to end of treatment (Week 8) in postherpetic patients. F=31.17; P<0.001.
Journal of Pain and Symptom Management  , 54-68DOI: ( /j.jpainsymman )
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions